-
1
Characteristics of CanPath participants (N = 134,404) who completed the follow-up questionnaire.
Published 2025Subjects: -
2
-
3
-
4
-
5
-
6
Enhancing dose selection in phase I cancer trials: Extending the Bayesian Logistic Regression Model with non-DLT adverse events integration
Published 2025Subjects: “…Bayesian Logistic Regression model…”
-
7
-
8
-
9
-
10